Global PD-L1 Biomarker Testing Market Growth (Status and Outlook) 2023-2029

Global PD-L1 Biomarker Testing Market Growth (Status and Outlook) 2023-2029

PD-L1 Biomarker Testing measures the amount of PDL1 on cancer cells. PDL1 is a protein that helps keep immune cells from attacking nonharmful cells in the body. Normally, the immune system fights foreign substances like viruses and bacteria, and not your own healthy cells. Some cancer cells have high amounts of PDL1. This allows the cancer cells to "trick" the immune system, and avoid being attacked as foreign, harmful substances.

Current PD-L1 testing is based on immunohistochemistry (IHC) methods. Immunohistochemistry (IHC) is the process whereby antibodies are used to detect proteins (antigens) in cells within a tissue section (for instance liver, pancreas or the heart).

PD-L1 is a ligand that binds to PD-1 (programmed cell death-1), expressed on activated T cells, to evade anti-tumor responses. PD-L1 plays a role in inhibiting T cell activation and proliferation and has emerged as an important target in cancer treatment. PD-L1 protein detection by immunohistochemistry (IHC) testing is widely used as a predictive biomarker assay for anti–PD-1/PD-L1 therapies.

PDL1 testing is used to find out if you have a cancer that may benefit from immunotherapy.

LPI (LP Information)' newest research report, the “PD-L1 Biomarker Testing Industry Forecast” looks at past sales and reviews total world PD-L1 Biomarker Testing sales in 2022, providing a comprehensive analysis by region and market sector of projected PD-L1 Biomarker Testing sales for 2023 through 2029. With PD-L1 Biomarker Testing sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world PD-L1 Biomarker Testing industry.

This Insight Report provides a comprehensive analysis of the global PD-L1 Biomarker Testing landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on PD-L1 Biomarker Testing portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global PD-L1 Biomarker Testing market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for PD-L1 Biomarker Testing and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global PD-L1 Biomarker Testing.

The global PD-L1 Biomarker Testing market size is projected to grow from US$ 1438.5 million in 2022 to US$ 4214.5 million in 2029; it is expected to grow at a CAGR of 16.6% from 2023 to 2029.

The classification of PD-L1 Biomarker Testing includes PD-L1 (22C3), PD-L1 (28-8), PD-L1 (SP142), PD-L1 (SP263) and Other, and the revenue proportion of PD-L1 (22C3) in 2019 is about 21.68%.

PD-L1 Biomarker Testing is widely used in Hospital and Diagnostic Laboratories. The most proportion of PD-L1 Biomarker Testing is Hospital, and the proportion in 2019 is about 52.7%.

North Americas is the largest consumption place, with a consumption market share nearly 55.63% in 2019. Following North Americas, Europe is the second largest consumption place with the consumption market share of 26.7%.

This report presents a comprehensive overview, market shares, and growth opportunities of PD-L1 Biomarker Testing market by product type, application, key players and key regions and countries.

Market Segmentation:

Segmentation by type
PD-L1 IHC 22C3 Assay
PD-L1 IHC 28-8 Assay
PD-L1 (SP142) Assay
PD-L1 (SP263) Assay

Segmentation by application
Hospital
Diagnostic Center
Others

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Agilent Technologies
Eli Lilly
AstraZeneca
Roche
Bristol-Myers Squibb
Merck
Pfizer

Please note: The report will take approximately 2 business days to prepare and deliver.